[go: up one dir, main page]

EA202190137A1 - Нафтиридиноновые соединения для применения в качестве активаторов t-клеток - Google Patents

Нафтиридиноновые соединения для применения в качестве активаторов t-клеток

Info

Publication number
EA202190137A1
EA202190137A1 EA202190137A EA202190137A EA202190137A1 EA 202190137 A1 EA202190137 A1 EA 202190137A1 EA 202190137 A EA202190137 A EA 202190137A EA 202190137 A EA202190137 A EA 202190137A EA 202190137 A1 EA202190137 A1 EA 202190137A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
cell activators
naphthyridine compounds
dgk
diacylglycerol kinase
Prior art date
Application number
EA202190137A
Other languages
English (en)
Inventor
Луис С. Чупак
Мин Динг
Роберт Г. Джентлис
Ячжун Хуан
Скотт У. Мартин
Ивар М. Макдоналд
Стивен Е. Мерсер
Ричард Е. Олсон
Упендер Велапарти
Майкл Вичроски
Сяофань Чжэн
Original Assignee
Бристол-Маерс Сквибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бристол-Маерс Сквибб Компани filed Critical Бристол-Маерс Сквибб Компани
Publication of EA202190137A1 publication Critical patent/EA202190137A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

В настоящем изобретении предложены соединения формулы (I)или соль указанных соединений, где R1, R2, R3 и R4 являются такими, как определено в данном описании. Также предложены способы применения таких соединений для ингибирования активности диацилглицеринкиназы альфа (DGK) или диацилглицеринкиназы дзета (DGK), или обоих этих ферментов, и фармацевтические композиции, содержащие такие соединения. Данные соединения можно применять для лечения вирусных инфекций и пролиферативных нарушений, таких как рак.
EA202190137A 2018-06-27 2019-06-26 Нафтиридиноновые соединения для применения в качестве активаторов t-клеток EA202190137A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862690444P 2018-06-27 2018-06-27
PCT/US2019/039131 WO2020006016A1 (en) 2018-06-27 2019-06-26 Naphthyridinone compounds useful as t cell activators

Publications (1)

Publication Number Publication Date
EA202190137A1 true EA202190137A1 (ru) 2021-05-17

Family

ID=67297314

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190137A EA202190137A1 (ru) 2018-06-27 2019-06-26 Нафтиридиноновые соединения для применения в качестве активаторов t-клеток

Country Status (24)

Country Link
US (1) US11866430B2 (ru)
EP (1) EP3814347B1 (ru)
JP (1) JP7373512B2 (ru)
KR (1) KR102804324B1 (ru)
CN (1) CN112585139B (ru)
AU (1) AU2019291792B2 (ru)
BR (1) BR112020026568A2 (ru)
CA (1) CA3104647A1 (ru)
DK (1) DK3814347T3 (ru)
EA (1) EA202190137A1 (ru)
ES (1) ES2950007T3 (ru)
FI (1) FI3814347T3 (ru)
HR (1) HRP20230627T1 (ru)
HU (1) HUE062412T2 (ru)
IL (1) IL279730B2 (ru)
LT (1) LT3814347T (ru)
MX (1) MX2020013373A (ru)
PL (1) PL3814347T3 (ru)
PT (1) PT3814347T (ru)
RS (1) RS64285B1 (ru)
SG (1) SG11202012973RA (ru)
SI (1) SI3814347T1 (ru)
SM (1) SMT202300170T1 (ru)
WO (1) WO2020006016A1 (ru)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
EP4065570A1 (en) 2019-11-28 2022-10-05 Bayer Aktiengesellschaft Substituted aminoquinolones as dgkalpha inhibitors for immune activation
BR112022010112A2 (pt) 2019-11-28 2022-09-06 Bayer Ag Aminoquinolonas substituídas como inibidores de dgkalfa para ativação imunológica
EP4065584A1 (en) 2019-11-28 2022-10-05 Bayer Aktiengesellschaft Substituted aminoquinolones as dgkalpha inhibitors for immune activation
JP2023510108A (ja) * 2019-12-19 2023-03-13 ブリストル－マイヤーズ スクイブ カンパニー Ｄｇｋ阻害剤およびチェックポイントアンタゴニストの組み合わせ
AR120823A1 (es) 2019-12-23 2022-03-23 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos útiles como activadores de células t
IL294273A (en) * 2019-12-23 2022-08-01 Bristol Myers Squibb Co Substituted heteroaryl compounds useful as t cell activators
US20230118629A1 (en) * 2019-12-23 2023-04-20 Bristol-Myers Squibb Company Substituted piperazine derivatives useful as t cell activators
SI4081305T1 (sl) 2019-12-24 2025-03-31 Carna Biosciences, Inc. Spojine, ki modulirajo diacilglicerol kinazo
LT4139286T (lt) * 2020-04-24 2025-05-12 Bayer Aktiengesellschaft Pakeisti aminotiazolai kaip dgkzeta inhibitoriai imuniteto aktyvavimui
WO2021258010A1 (en) 2020-06-19 2021-12-23 Gossamer Bio Services, Inc. Oxime compounds useful as t cell activators
JP7604067B2 (ja) * 2020-11-26 2024-12-23 エルジー・ケム・リミテッド ジアシルグリセロールキナーゼ阻害剤としての複素環化合物及びその用途
WO2022133083A1 (en) 2020-12-16 2022-06-23 Gossamer Bio Services, Inc. Compounds useful as t cell activators
EP4301755A1 (en) 2021-03-03 2024-01-10 Juno Therapeutics, Inc. Combination of a t cell therapy and a dgk inhibitor
CN117396478A (zh) * 2021-06-23 2024-01-12 吉利德科学公司 二酰基甘油激酶调节化合物
US11932634B2 (en) * 2021-06-23 2024-03-19 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
KR20240023629A (ko) * 2021-06-23 2024-02-22 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
KR20240023628A (ko) 2021-06-23 2024-02-22 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
WO2023122777A1 (en) * 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Oxime derivatives useful as t cell activators
EP4472963A1 (en) * 2022-02-01 2024-12-11 Arvinas Operations, Inc. Dgk targeting compounds and uses thereof
AU2023227010A1 (en) 2022-03-01 2024-09-12 Insilico Medicine Ip Limited Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
WO2023165528A1 (en) * 2022-03-01 2023-09-07 Insilico Medicine Ip Limited Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
WO2023165525A1 (en) * 2022-03-01 2023-09-07 Insilico Medicine Ip Limited Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
WO2023184327A1 (en) * 2022-03-31 2023-10-05 InventisBio Co., Ltd. Kinase inhibitors, preparation methods and uses thereof
EP4561561A2 (en) * 2022-07-29 2025-06-04 Septerna, Inc. Substituted 3,4-dihydroquinolinone inhibitors of tshr
EP4568963A1 (en) 2022-08-09 2025-06-18 Bristol-Myers Squibb Company Tertiary amine substituted bicyclic compounds useful as t cell activators
KR20250061756A (ko) 2022-09-08 2025-05-08 주노 쎄러퓨티크스 인코퍼레이티드 T 세포 요법과 연속적 또는 간헐적 dgk 억제제 투여의 조합
AR131785A1 (es) 2023-02-06 2025-04-30 Bayer Ag Combinaciones de inhibidores de dgk (diacilglicerol quinasa)
WO2025030002A2 (en) * 2023-08-02 2025-02-06 Arvinas Operations, Inc. Dgk targeting compounds and uses thereof
WO2025061020A1 (zh) * 2023-09-21 2025-03-27 楚浦创制（武汉）医药科技有限公司 苯并五元杂环衍生物及其制备方法与应用、药物组合物

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4324893A (en) 1979-04-18 1982-04-13 American Home Products Corporation 4-Amino-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives
MY140679A (en) 2001-05-24 2010-01-15 Avanir Pharmaceuticals Inhibitors of macrohage migration inhibitory factor and methods for identifying the same
BR0312204A (pt) 2002-06-27 2005-04-26 Schering Ag Antagonista de receptor ccr5 de quinolina substituìda
GB0230018D0 (en) 2002-12-23 2003-01-29 Syngenta Ltd Fungicides
TW200418829A (en) 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
JP2006521400A (ja) 2003-03-26 2006-09-21 バイエル・フアーマシユーチカルズ・コーポレーシヨン 糖尿病及び関連障害の処置のための化合物及びそれらの使用
GB0316915D0 (en) 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
CN1867334A (zh) 2003-07-22 2006-11-22 詹森药业有限公司 作为c－fms激酶抑制剂的喹啉酮衍生物
CN1839133A (zh) * 2003-08-22 2006-09-27 阿文尼尔药品公司 作为巨噬细胞移动抑制因子的抑制剂的取代的二氮杂萘衍生物及其在治疗人类疾病中的应用
US7381401B2 (en) 2004-01-08 2008-06-03 The University Of Chicago T cell anergy is reversed by active Ras and regulated by diacylglycerol kinase
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
PT2343320T (pt) 2005-03-25 2018-01-23 Gitr Inc Anticorpos anti-gitr e as suas utilizações
EA026785B1 (ru) 2005-05-10 2017-05-31 Инсайт Холдингс Корпорейшн Модуляторы индоламин 2,3-диоксигеназы и способы их применения
ME02260B (me) 2005-07-01 2016-02-29 Medarex Inc Humana monoklonska antitela za ligand programirane smrti 1 (pd-l1)
JP5294874B2 (ja) 2005-12-20 2013-09-18 インサイト・コーポレイション インドールアミン２，３−ジオキシゲナーゼのモジュレーターとしてのｎ−ヒドロキシアミジノヘテロ環
GB0605689D0 (en) * 2006-03-21 2006-05-03 Novartis Ag Organic compounds
JP2007308402A (ja) 2006-05-17 2007-11-29 Sumitomo Chemical Co Ltd シンナモイル化合物及びその用途
JP2007308441A (ja) 2006-05-22 2007-11-29 Sumitomo Chemical Co Ltd 含複素環化合物及びその用途
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
US20080125470A1 (en) 2006-09-19 2008-05-29 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
CA2693677C (en) 2007-07-12 2018-02-13 Tolerx, Inc. Combination therapies employing gitr binding molecules
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
EP2227233B1 (en) 2007-11-30 2013-02-13 Newlink Genetics Ido inhibitors
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
WO2010042489A2 (en) 2008-10-06 2010-04-15 Emory University Aminoquinoline derived heat shock protein 90 inhibitors, methods of preparing same, and methods for their use
MY188826A (en) 2008-12-09 2022-01-06 Genentech Inc Anti-pd-l1 antibodies and their use to enhance t-cell function
WO2010088408A2 (en) 2009-01-28 2010-08-05 Emory University Subunit selective nmda receptor antagonists for the treatment of neurological conditions
EP3023438B1 (en) 2009-09-03 2020-03-11 Merck Sharp & Dohme Corp. Anti-gitr antibodies
EP2493862B1 (en) 2009-10-28 2016-10-05 Newlink Genetics Corporation Imidazole derivatives as ido inhibitors
ES2557454T3 (es) 2009-12-10 2016-01-26 F. Hoffmann-La Roche Ag Anticuerpos que se unen al dominio extracelular 4 de CSF1R humana y su utilización
MA34062B1 (fr) 2010-03-04 2013-03-05 Macrogenics Inc Anticorps réagissant avec b7-h3, fragments immunologiquement actifs associés et utilisations associées
CN102918061B (zh) 2010-03-05 2016-06-08 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
EP2542587A1 (en) 2010-03-05 2013-01-09 F. Hoffmann-La Roche AG Antibodies against human csf-1r and uses thereof
TW202112827A (zh) 2010-05-04 2021-04-01 美商戊瑞治療有限公司 與集落刺激因子１受體（ｃｓｆ１ｒ）結合之抗體類
EP2592933B1 (en) 2010-07-16 2017-04-05 Anderson Gaweco Mif inhibitors and their uses
KR101527297B1 (ko) 2010-09-09 2015-06-26 화이자 인코포레이티드 4-1ｂｂ 결합 분자
WO2012142498A2 (en) 2011-04-13 2012-10-18 Innovimmune Biotherapeutics, Inc. Mif inhibitors and their uses
NO2694640T3 (ru) 2011-04-15 2018-03-17
SMT201800294T1 (it) 2011-04-20 2018-07-17 Medimmune Llc Anticorpi e altre molecole che legano b7-h1 e pd-1
RS61033B1 (sr) 2011-11-28 2020-12-31 Merck Patent Gmbh Antitela na pd-l1 i njihova upotreba
EP2791174B1 (en) 2011-12-15 2018-02-28 F. Hoffmann-La Roche AG Antibodies against human csf-1r and uses thereof
KR20140127855A (ko) 2012-02-06 2014-11-04 제넨테크, 인크. Csf1r 억제제를 사용하는 조성물 및 방법
AR089939A1 (es) 2012-02-09 2014-10-01 Glenmark Pharmaceuticals Sa COMPUESTOS BICICLICOS COMO INHIBIDORES DE mPGES-1
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
HK1208233A1 (en) 2012-05-11 2016-02-26 戊瑞治疗有限公司 Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
CA2882804A1 (en) 2012-08-31 2014-03-06 Brian Wong Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
US9937205B2 (en) 2012-09-04 2018-04-10 The Trustees Of The University Of Pennsylvania Inhibition of diacylglycerol kinase to augment adoptive T cell transfer
CN105051043B (zh) 2012-11-16 2017-05-10 默克专利有限公司 用作激酶活性调节剂的新颖的杂环类衍生物
CA2981530A1 (en) 2015-04-10 2016-10-13 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
ES2981114T3 (es) 2015-12-17 2024-10-07 Merck Patent Gmbh 8-ciano-5-piperidino-quinolinas como antagonistas de TLR7/8 y sus usos para el tratamiento de trastornos inmunitarios
WO2017177037A1 (en) 2016-04-06 2017-10-12 University Of Virginia Patent Foundation Compositions and methods for treating cancer
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
EP4001269A1 (en) 2016-12-22 2022-05-25 Amgen Inc. Benzoisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer
GB201700814D0 (en) 2017-01-17 2017-03-01 Liverpool School Tropical Medicine Compounds
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
US12187687B2 (en) 2017-06-26 2025-01-07 University Of Virginia Patent Foundation Compositions and uses thereof

Also Published As

Publication number Publication date
JP7373512B2 (ja) 2023-11-02
EP3814347B1 (en) 2023-05-03
IL279730B1 (en) 2023-08-01
AU2019291792A1 (en) 2021-02-11
IL279730B2 (en) 2023-12-01
US11866430B2 (en) 2024-01-09
EP3814347A1 (en) 2021-05-05
CN112585139B (zh) 2023-12-01
BR112020026568A2 (pt) 2021-03-23
SI3814347T1 (sl) 2023-07-31
MX2020013373A (es) 2021-03-09
KR102804324B1 (ko) 2025-05-08
IL279730A (en) 2021-03-01
KR20210024587A (ko) 2021-03-05
SMT202300170T1 (it) 2023-09-06
CN112585139A (zh) 2021-03-30
PL3814347T3 (pl) 2023-07-24
AU2019291792B2 (en) 2022-09-29
CA3104647A1 (en) 2020-01-02
PT3814347T (pt) 2023-07-18
FI3814347T3 (fi) 2023-06-12
ES2950007T3 (es) 2023-10-04
HUE062412T2 (hu) 2023-10-28
US20210277004A1 (en) 2021-09-09
LT3814347T (lt) 2023-07-10
WO2020006016A1 (en) 2020-01-02
DK3814347T3 (da) 2023-08-07
JP2021528469A (ja) 2021-10-21
HRP20230627T1 (hr) 2023-09-29
RS64285B1 (sr) 2023-07-31
SG11202012973RA (en) 2021-01-28

Similar Documents

Publication Publication Date Title
EA202190137A1 (ru) Нафтиридиноновые соединения для применения в качестве активаторов t-клеток
ZA202203515B (en) Substituted pyridopyrimidinonyl compounds useful as t cell activators
MX2020013817A (es) Compuestos de naftiridinona sustituidos utiles como activadores de celulas t.
MX2022005839A (es) Compuestos utiles como inhibidores de la proteina helios.
BR112022012204A2 (pt) Compostos de heteroarila substituída úteis como ativadores de célula t
BR112022012220A2 (pt) Compostos de piperazina quinolinonil substituída úteis como ativadores de célula t
BR112022012222A2 (pt) Derivados de piperazina substituídos úteis como ativadores de células t
BR112022012179A2 (pt) Compostos de quinazolina substituída úteis como ativadores de célula t
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
CL2022001710A1 (es) Derivados bicíclicos sustituidos de piperidina útiles como activadores de células t
BR112015022462A8 (pt) inibidores de ido, composição farmacêutica, método de inibição de atividade de indolamina 2,3-dioxigenase e uso dos referidos inibidores
EA201792231A1 (ru) Ингибиторы индоламин-2,3-диоксигеназы и способы их применения
EA201691428A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4
PH12018502026A1 (en) Substituted indole compound derivatives as dengue viral replication inhibitors
PH12021500034A1 (en) Compounds useful in hiv therapy
GEP20227353B (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
EA202090448A1 (ru) Дигидрооксадиазиноны
EA201591541A1 (ru) Ингибиторы бета-секретазы 1 (bace 1)
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
TW201613864A (en) Novel compounds
MX2023011065A (es) Derivados de heteroarilos biciclicos como inhibidores de ectonucleotido pirofosfatasa fosfodiesterasa 1.
MX2022000811A (es) Inhibidores de enzimas.
PH12020551034A1 (en) Pi4kiiibeta inhibitors
MX379704B (es) Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida
EA202191588A1 (ru) Замещенные ксантиновые производные